VEGFA and renal carcinoma: Anti‐angiogenic cancer therapy, given either as a neutralizing anti‐vascular endothelial growth factor (VEGFA) antibody (bevacizumab) or as receptor tyrosine kinase inhibitors (sunitinib and sorafenib), increases the progression‐free survival or overall survival in several cancer forms including metastatic colon cancer, advanced lung cancer, renal cancer, and hepatocellular carcinoma 2.